Introduction
Multiple drug resistance (MDR) is defined as resistance to one drug accompanied by resistance to other drugs that may have different structures and mechanisms of action. 1 The identification of the membrane transporter P-glycoprotein (Pgp) provided the first significant advance in the understanding of MDR. 2 This was followed by other members of the adenosine triphosphate (ATP)-binding cassette (ABC) transporter family, which are known to catalyse the efflux of many structurally unrelated anticancer drugs. 2 Many types of compound are able to overcome Pgpmediated MDR, including calcium channel blockers (e.g. verapamil, nifedipine), hypotensive drugs (reserpine), antibiotics (cephalosporins, gramicidin, puromycin), immuno suppressants (cyclosporin A and its H Sui, Z-Z Fan, Q Li ABCB1/Pgp-mediated multiple drug resistance derivatives), and other lipophilic compounds. 3 The existence of numerous Pgp inhibitors together with the multiple signal transduction pathways involved in the emergence of MDR has led to difficulty in determining the most effective therapy for Pgp-mediated MDR.
Signal transduction pathways are controlled by the binding of signalling molecules to membrane proteins, causing the activation of cytoplasmic proteins that, ultimately, activate transcription factors. Various signalling pathways and transcription factors are known to influence the response to Pgp-mediated MDR, including the Ras-mediated pathway, 4 -20 cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA) pathway, 21, 22 phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) pathway, 23 -26 Y-box binding protein 1 (YB-1), 27, 28 phosphatase and tensin homologue (PTEN), 29 -33 p53, 34, 35 protein kinase C 36 -41 and other protein kinases.
This review discusses the roles of signal transduction pathways and transcription factors in the acquisition of Pgp-mediated MDR in previously drug-sensitive cancers.
Search strategy
This review included original research papers and review articles published between 1985 and 2011 and listed on the PubMed database. A systematic literature search of the PubMed database was conducted using the key words 'signal transduction pathway', 'multidrug resistance' and 'cancer'. The search was restricted to English language papers only. The full text of all papers identified in the search was reviewed by all three authors and the reference lists of included papers were reviewed for any further relevant papers. Certain types of publication were excluded, including case reports, case-control studies, cohort studies and conference proceedings.
In total, 700 papers were identified in the initial search. Papers that did not evaluate the relationship between ABCB1/Pgpmediated drug efflux and ABCB1 gene expression were excluded, leaving approximately 200 papers. Additionally, papers describing 'pathways' other than signal transduction pathways were excluded, leaving a total of 75 papers that were included in the final review.
MDR and cellular drug efflux
Chemotherapeutic drugs commonly enter cells by passive diffusion through the plasma membrane, and the structure of the cell membrane is, therefore, likely to be the main cause of decreased drug accumulation in MDR. 42 In cancer patients who do not respond to chemotherapy, MDR is usually mediated by the overexpression of various ATP-dependent efflux pumps located on the cytoplasmic side of the membrane, resulting in increased drug efflux from the resistant cell. 43 Several studies using a broad range of tumour cell lines and drugs have found that cellular transport proteins of the ABC family are involved in the penetration of drugs through the cell membrane and their intracellular accumulation to effective concentrations. 44, 45 There are known to be at least 48 types of ABC transporters involved in MDR, 46 including Pgp (encoded by the ABCB1 gene), MDR-associated protein 1 (MRP1, encoded by the ABCC1 gene) and ABC subfamily G member 2 (encoded by the ABCG2 gene, also known as breast cancer resistance protein [BCRP]). 47
The role of Pgp
The transmembrane glycoprotein, Pgp, is a large glycoprotein (approximately 170 kDa) and its role in MDR has been studied H Sui, Z-Z Fan, Q Li ABCB1/Pgp-mediated multiple drug resistance extensively. Pgp is able to transport cytotoxic drugs as well as amphiphilic, neutral or cationic molecules, and it is present in tissues involved in absorption, metabolism and the action of drugs and environmental toxins. 48 Reduced intracellular drug accumulation and the MDR phenotype are associated with elevated Pgp levels. 48, 49 Pgp is normally found in the liver, kidney, colon, small intestine and blood-brain barrier. 50 Pgp functions as a barrier, reducing intracellular chemical concentration via active efflux against concentration gradients. 45 It is thought that the drug molecule may bind to a specific site within Pgp and is subsequently transported out of the cell via ATP hydrolysis. 51 Pgp inhibitors may, therefore, offer effective treatment of MDR.
The role of ABCB1
In humans, Pgp is encoded by the ABCB1 gene that is localized to 7q21 and is believed to have arisen from an internal duplication of a primordial sequence. 52 Pgp production is regulated by both the level of protein synthesis and by alternate processing, suggesting that gene-transcription factor interactions may play an intermediary role in the transduction of information from promoter-bound Pgp to the basal transcriptional machinery. Some studies have demonstrated that Pgp activity may be influenced directly by the function of its own gene, mediated by drug-induced activation of ABCB1. 53 There is a significant association between ABCB1 allele frequencies and histological type, stage and grade in carcinoma of the breast. 54 ABCB1 mRNA was detected in samples from patients with chronic myeloid leukaemia but was not present in a non-MDR cell line. 53 These findings provide support for an acquired Pgp expression model involving ABCB1 activation, but very little is known regarding the mechanism involved. Studies on the role of signal crosstalk in the transcriptional control of ABCB1 indicate that ABCB1 is a target of the Ras/Raf signalling pathway. 55, 56 Signal transduction pathways in ABCB1/ Pgp-mediated MDR An overview of signal transduction pathways and transcriptional activation mechanisms involved in mediating the acquisition of Pgp-mediated MDR is shown in Fig. 1 .
MAPK
The Ras/MAPK (mitogen-activated protein kinase, originally known as the ERK [extracellular signal-regulated kinase]) pathway is probably the best characterized signal transduction pathway in cell biology. Cytotoxic anticancer drugs have been shown to induce stress pathways via the MAPK/MAPK kinase (MAPKK)/MAPKK kinase (MAPKKK) pathway, which is made up of three consecutive kinases. 4 Specific inhibitors of the MAPK pathway significantly reduced the survival of ABCB1/Pgp-mediated MDR cancer cells, suggesting that the activation of pathways leading to ABCB1/Pgp overexpression is an intrinsic MDR phenotype. 5, 6 Novel derivatives of tetrandrine 7 and 3-(5′hydroxymethyl-2′-furyl)-1-benzylindazole 8 have been shown effectively to reverse Pgpmediated MDR by inhibiting the MAPK signalling pathway.
JNK
The c-Jun NH 2 -terminal kinase (JNK) is a member of the MAPK family that binds to and phosphorylates the NH 2 -terminal activation domain of the transcription factor H Sui, Z-Z Fan, Q Li ABCB1/Pgp-mediated multiple drug resistance c-Jun. 9 Evidence suggests that JNK modulates the development of the MDR phenotype. 10 -12 JNK is present in a more highly activated form in Pgp-associated MDR variants of the human cervical carcinoma cell line KB-3, suggesting that activation of JNK may be an important aspect of the cellular response to a variety of anticancer drugs and may be involved in the development of the MDR phenotype. 13 The overexpression of the MAP3K1 gene (also known as MEKK 1, which encodes MAPKKK 1) in the human cell line HeLa selectively activated JNK, leading to an increase in the levels of ABCB1 mRNA and Pgp protein. 14 Several studies have found that the JNK signalling pathway may be involved in regulating activity of ABCB1 and Pgp. 12, 15 
P38 MAPK
The first identification of p38 was in mammalian cells as a MAP kinase targeted by endotoxin and hyperosmolarity. 16 p38 MAPK downstream signalling is a common feature of apoptosis and may influence the cellular response to drug treatment. 17, 20 The MDR phenotype was associated with increased levels and activity of p38 MAPK in the murine leukaemia cell line L1210/VCR, and SB203580 (an inhibitor of the p38 MAPK pathway) 17 Several drugs are available that act to counter apoptosis resistance via p38 MAPK, including calebin-A, 18 tanshinone IIA, 19 and T138067. 20 The lack of clinical success of these drugs may be due to MDR being caused by the activity of several signal transduction pathways and not only p38 MAPK.
CAMP-DEPENDENT PROTEIN KINASE
The roles of cAMP-dependent PKA and its activator cAMP in the development of the ABCB1/Pgp-induced MDR phenotype have been extensively studied. cAMP is synthesized from ATP by the plasma membrane bound adenylyl cyclase and rapidly broken down via hydrolysis to adenosine 5′-monophosphate (5′-AMP) by cAMP phosphodiesterases. 57 Numerous extracellular signals exist, which lead to cAMP-dependent activation of PKA-related proteins that could result in activation of the multispecific MDR1 drug transporter. 21 Activation of ABCB1 occurs via a cAMPdependent PKA pathway in primary rat hepatocytes, 22 suggesting that cAMP/PKA phosphatase activity modulates ABCB1/Pgp expression.
MAPK 58 and PI3K/Akt 59 signalling are also known to affect cAMP and PKA. It is likely that the MDR phenotype involves interaction between several signalling pathways.
PI3K
The PI3K signalling pathway is known to influence drug resistance. The PI3Ks are a family of lipid kinases that propagate intracellular signalling cascades regulating a wide range of cellular processes. 60 Studies have found that PI3K is an effector of Rasmediated oncogenic signalling, and PI3Kγ activated H-Ras G12V in vivo or GTPγS-loaded H-Ras in vitro. 23 PI3K and Akt are upstream signals in Rac activation, which is associated with the induction of ABCB1 expression and may contribute to the evolution of drug resistance in liver cancer. 24 Although PI3K activation may be necessary for K-Rasinduced MDR, preliminary studies suggest that inhibition of PI3K signalling alone may not be the only way to treat ABCB1/Pgpmediated MDR effectively in vitro. 25 Activation of multiple signal transduction pathways, including the PI3K/Akt pathway and MAPK cascade, induced chemoresistance in cancer cells. 26 These studies suggest that established cancers with Rasmediated pathways may not be sensitive to single-agent PI3K pathway inhibitors.
PKC
Protein kinase C (PKC) is an isoenzyme family with serine/threonine kinase function that has been shown to play a key role in the signal transduction pathway elicited by a variety of extracellular stimuli, such as growth factors, hormones and neurotransmitters. 61 Early observations led to the consideration of PKC as a downstream effector of the Ras system. 36 In addition, phorbol ester activation of PKC induced a transient MDR phenotype in wild-type human breast cancer cells, which was associated with decreased intracellular drug accumulation and increased drug resistance. 37 Fine et al. 37 reported that cellular PKC activity was elevated in doxorubicin-selected MCF7-MDR cells compared with the parental cells. This was subsequently attributed to a 30-fold increase in PKCα and a decrease in other PKC isozymes in the drug-selected cells. 38 This finding taken together with others leads to the belief that phorbol ester PKC activation induces resistance to chemotherapeutic drugs and causes a corresponding reduction in intracellular drug accumulation. 39 -41 H Sui, Z-Z Fan, Q Li ABCB1/Pgp-mediated multiple drug resistance
Gene transcription and transacting factors

NF-kB
Nuclear factor κB (NF-κB) is a protein complex that acts as a transcription factor. NF-κB is activated in tumour cells by mutations in genes encoding NF-κB and in genes that control NF-κB activity such as the inhibitor of κB. 62 Chromosomal alterations of NF-κB family genes have frequently been found in MDR human cancers, indicating that this transcription factor also plays a crucial role in MDR. 63 Activation of ABCB1 was shown to occur via activation of an NF-κB binding site (located between base pairs -167 and -158 of the gene encoding NF-κB). 64 Both the antisense p65 subunit of NF-κB or dominant negative Raf-1 kinase blocked insulin-induced ABCB1 promoter activity. 64 Because the expression of MDR ABCB1 appears to be NF-κB dependent, inhibitors of this transcription factor used in cancer chemotherapy may have the additional desirable effect of helping to prevent or overcome MDR. The role of NF-κB in ABCB1/Pgp regulation appears to be more complex, however. NF-κB has been shown to repress ABCB1 transcription, 65 and activation of NF-κB protects MDR cells against various toxic stimuli but also promotes apoptosis in combination with a cytotoxic agent to overcome MDR. 66 Thus, NF-κB appears to play a dual role in the regulation of ABCB1, as an intermediate for rapid activation in response to stress and a transcriptional repressor in cells that have been chronically exposed to chemotherapeutic agents.
TNF-a
Tumour necrosis factor (TNF)-α shows promise as an anticancer therapeutic agent by affecting immunity and cellular remodelling and influencing apoptosis and cell survival. 67 TNF-α is a 17 kDa polypeptide first described as a serumderived substance that causes tumour cell death. 68 Evidence from numerous studies indicates that expression and activity of ABCB1/Pgp can be controlled by the activity of TNF-α. For example, TNF-α may activate fresh cytotoxic pathways in MDR tumour cells, via type I (p55) TNF receptors and apoptosis. 69 Further studies have found that cells resistant to vincristine and doxorubicin are regulated by a TNF-α mediated NF-κB signalling pathway, and inhibition of TNF-α or NF-κB may be a useful treatment for MDR leukaemias. 70 TNF-α stimulates the NF-κBinduced loss of mRNA encoding the myogenic transcription factor MyoD, which causes muscle decay in mice. 71 Many different pathways of signal transduction are involved in the regulation of TNF-α, and recent advances in the understanding of upstream and downstream events may allow MDR to be overcome.
PTEN
The 403 amino acid protein, PTEN, which has dual lipid and protein phosphatase functions is present on the plasma membrane and in the nucleus. In humans, the gene encoding PTEN is located on the long (q) arm of chromosome 10 at position 23.3. 72 PTEN has a role in MDR and the regulation of PI3K/Akt. 73 The PTEN network encompasses signals from cell surface growth factor receptors to nuclear transcription factors and includes connections to other tumour suppressor and oncogenic signalling pathways. 29 PTEN keeps cellular phosphatidylinositol 3,4,5triphosphate (PIP 3 ) at a low level in vivo, removing the 3′-phosphate from PI3Kgenerated PIP 3 and converting it to phosphatidylinositol 4,5-diphosphate. 30 The protein phosphatase activity of PTEN is H Sui, Z-Z Fan, Q Li ABCB1/Pgp-mediated multiple drug resistance suppressive with a dual role in tumorigenesis. Reduction of PTEN in the human adenocarcinoma cell line OVCAR-3 resulted in the development of MDR. 31 These alterations conferred cisplatin resistance via PTEN-mediated activation of the PI3K/Akt signalling pathway in a blockade of apoptosis. 31 PTEN is able to alter cell sensitivity to drugs, depending on the mechanism of action of the drug, and lead to other specific signalling environments (MAPK, p53, B-cell lymphoma 2 [Bcl-2], etc.) that could induce Pgp-mediated MDR in various cancers. 32
SP1
Specificity protein 1 (Sp1) was the first acetylene-type zinc finger-containing transcription factor to be isolated and cloned from mammalian cells. It regulates many proteins, particularly those involved in the regulation of nucleic acid biosynthesis and metabolism (including thymidylate synthase, adenine deaminase and DNA polymerase) and regulation of the cell cycle or proliferation (such as cyclin D 1 , E2F, c-fos, transforming growth factor [TGF]-α). 33 Although studies on Sp1 and MDR are limited, data suggest that Sp1 is involved in ABCB1 promoter activation. 74 Although Sp1 is known specifically to regulate the transcription of genes via different proteinprotein interactions, 75 the role of hormonedependent regulation of differential gene expression is complex.
Conclusions
Studies of the genes and signalling pathways involved in the regulation of Pgp activity indicate the involvement of multiple pathways. Evidence suggests that ABCB1 overexpression, caused by one or more signal transduction pathways or transcription factors, is associated with the acquired drug-induced MDR phenotype. It is probable that other, less well studied factors or pathways are involved in MDR, such as p53, PKA, YB-1, caspase 3, caspase 9, or TGF-β 1 . Studies on the inhibition of different transcription factors would help to elucidate the MDR phenotype and be clinically beneficial.
Various signal transduction pathways, transcription factors and molecular events (in addition to transcriptional/translational regulation) are involved in regulation of the ABCB1/Pgp-induced MDR phenotype. Advances in understanding the mechanisms regulating ABCB1 expression under a variety of environmental conditions have provided potential targets for novel therapeutic intervention, including MRPs, BCRP, lung resistance-related protein, topoisomerase II, and glutathione-S-transferase-π topoisomerase activity. ABCB1 is not the only gene for which aberrant expression contributes to the MDR phenotype. In order for inhibitors of transcription factors to function effectively as targeted anticancer drugs in a clinical setting, more research is needed for a better understanding of the interplay between these various transporters and regulators and their roles in the MDR of individual tumours.
